Techniques like laparoscopic and robotic esophagectomy are becoming increasingly refined, offering patients faster recovery times and improved quality of life. https://pubmed.ncbi.nlm.nih.gov/38492067/
Tap Below to Listen
Tap Below to Listen
The promise of immunotherapy for esophageal cancer is being actively explored. Checkpoint inhibitors are showing potential to improve outcomes in patients with advanced disease.
In selected patients post post-operative Nivolumab (Immunotherapy) increases survival.
The identification of specific genetic mutations associated with esophageal cancer is covering the way for the development of targeted therapies. These therapies attack cancer cells with greater precision and potentially fewer side effects.
Dr Harsh Shah is a specialized esophageal cancer surgeon in Ahmedabad.
He is practising at Apollo Hospital, Ahmedabad.
Dr Harsh Shah is a specialized esophageal cancer surgeon in Ahmedabad. He is practising at Apollo Hospital, Ahmedabad.
WhatsApp us